Interpretation of the evidence for the efficacy and safety of statin therapyRory Collins, Richard Peto, Christina Reith et al.|The Lancet|2016Cited by 1.8k
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trialsSøren Lund Kristensen, John J.V. McMurray, Rasmus Rørth et al.|The Lancet Diabetes & Endocrinology|2019Cited by 1.6k
Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trialsColin Baigent, Faı̈ez Zannad, Martin Landray et al.|The Lancet|2022Cited by 969
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trialsDaniel I. Swerdlow, Rudi G. J. Westendorp, David Preiss et al.|The Lancet|2014Cited by 709
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysisGemma Currie, Patrick B. Mark, Alison Taylor et al.|BMC Nephrology|2016Cited by 209